Similar Posts
The Certified Methadone Advocate Course
ByAdminAdmin 03/02/2023Saturday, October 16, 2004 Preconference Events Frederick W. Christie, MA AFIRM Long Island, New York H. Westley Clark, MD, JD, MPH CSAT Rockville, MD Stewart Leavitt, PHD Addiction Treatment Forum Glenview, IL James P. Connolly, CMA PA NAMA Newtown, PA Herman Joseph, PHD, CMA NAMA New York, NY J. Thomas Payte, MD, CMA Colonial Management…
The President’s Office
ByAdminAdmin 08/17/2022Methadone treatment is entering a new era giving methadone patients opportunities that they never had before. Our views and issues are being taken seriously by many and it is important that advocacy organizations continue their important role as the patient’s voice. It is because of the hard work of many of the NAMA chapters that…
Affordable Care Act
ByAdminAdmin 08/28/2021Resources Equal Parity On March 23, 2010, President Obama signed the Affordable Care Act (ACA) into law. This puts in place comprehensive health insurance reforms that will roll out over four years and beyond. Health reform includes several key steps in the next 4 years. Medicaid will be expanded to allow more people at the lowest…
Answer one
ByAdminAdmin 12/31/2022FALSE! Current research shows that doses below 60 mg/day are “not effective and hence not appropriate” and that low dose policies for pregnant and non-pregnant patients are associated with increased drug use as well as reduced program retention. Medical withdrawal of opioid dependent women is not recommended in pregnancy because of increased risk to the…
Orlaam(LAAM) Alert
ByAdminAdmin 06/17/2021FDA Warns About Orlaam T01-15 Print Media: 301-827-6242 April 20, 2001 Broadcast Media: 301-827-3434 Consumer Inquiries: 888-INFO-FDA The U.S. Food and Drug Administration (FDA) issued a new warning about health risks associated with levomethadyl acetate HC, a.k.a. Orlaam, a drug used to treat opiate addiction. FDA Announces Labeling Changes Following Cardiac Adverse Events With…